• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期突变型胃型宫颈腺癌的非部位特异性PARP抑制剂维持治疗：一例报告

Site-agnostic PARP-inhibitor maintenance therapy of advanced stage mutated gastric-type endocervical adenocarcinoma: A case report.

作者信息

Tostrud Lauren Jill, Somasegar Sahana, Renz Malte

机构信息

Department of Obstetrics & Gynecology, Stanford University School of Medicine, Palo Alto, CA, United States.

Gynecologic Oncology Division, Stanford University School of Medicine, Palo Alto, CA, United States.

出版信息

Gynecol Oncol Rep. 2024 May 1;53:101406. doi: 10.1016/j.gore.2024.101406. eCollection 2024 Jun.

DOI:10.1016/j.gore.2024.101406
PMID:38736717
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11088272/
Abstract

• Gastric-type endocervical adenocarcinomas (GEA) are rare, aggressive cancers with limited therapeutic options. • Although therapeutic effects of PARP-inhibitors in non-BRCA-associated cancers might be limited, clinical data is sparse. • Given limited treatment options and poor prognosis of GEA, somatic mutation testing, and PARP-inhibitor maintenance can be considered.

摘要

• 胃型宫颈内膜腺癌（GEA）是罕见的侵袭性癌症，治疗选择有限。

• 虽然PARP抑制剂在非BRCA相关癌症中的治疗效果可能有限，但临床数据稀少。

• 鉴于GEA的治疗选择有限且预后不良，可考虑进行体细胞突变检测和PARP抑制剂维持治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/497be093681f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/573cf9459a99/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/3b2a68ac3428/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/497be093681f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/573cf9459a99/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/3b2a68ac3428/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a774/11088272/497be093681f/gr2.jpg

相似文献

1
Site-agnostic PARP-inhibitor maintenance therapy of advanced stage mutated gastric-type endocervical adenocarcinoma: A case report.晚期突变型胃型宫颈腺癌的非部位特异性PARP抑制剂维持治疗：一例报告
Gynecol Oncol Rep. 2024 May 1;53:101406. doi: 10.1016/j.gore.2024.101406. eCollection 2024 Jun.
2
Molecular characterization of gastric-type endocervical adenocarcinoma using next-generation sequencing.采用下一代测序技术对胃型宫颈内膜腺癌进行分子特征分析。
Mod Pathol. 2019 Dec;32(12):1823-1833. doi: 10.1038/s41379-019-0305-x. Epub 2019 Jul 15.
3
A retrospective study on incidence, diagnosis, and clinical outcome of gastric-type endocervical adenocarcinoma in a single institution.单中心胃型宫颈内膜腺癌的发病、诊断和临床结局的回顾性研究。
Diagn Pathol. 2021 Jul 31;16(1):68. doi: 10.1186/s13000-021-01129-9.
4
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of Mutation Status.TRAIL受体靶向剂可增强PARP抑制剂在胰腺癌中的疗效，且与突变状态无关。
Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.
5
Huge Ovarian Tumor: An Unusual Presentation of Gastric-Type Endocervical Adenocarcinoma.巨大卵巢肿瘤：胃型宫颈内膜腺癌的一种不寻常表现
Case Rep Oncol. 2022 Nov 8;15(3):1009-1013. doi: 10.1159/000527040. eCollection 2022 Sep-Dec.
6
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.BRCA2 种系突变可识别出对 PARP 抑制剂有反应的胃癌。
Cancer Res. 2023 May 15;83(10):1699-1710. doi: 10.1158/0008-5472.CAN-22-2620.
7
Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.携带BRCA2突变的转移性透明细胞子宫内膜腺癌对聚（ADP核糖）聚合酶（PARP）抑制剂奥拉帕尼的完全缓解
Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080. eCollection 2022 Jan-Feb.
8
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.比利时一项基于精准肿瘤的 II 期、不限癌种的临床试验，评估奥拉帕利治疗携带有胚系或体细胞 BRCA1/2、CHEK2 或 ATM 基因突变的晚期癌症患者的疗效。
ESMO Open. 2023 Dec;8(6):102041. doi: 10.1016/j.esmoop.2023.102041. Epub 2023 Oct 16.
9
A Rare Case of Endocervical Adenocarcinoma of Gastric Type.1例罕见的胃型宫颈管腺癌
Cureus. 2022 Dec 28;14(12):e33059. doi: 10.7759/cureus.33059. eCollection 2022 Dec.
10
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases.子宫颈原位胃型腺癌：两例的细胞学和组织病理学特征
Virchows Arch. 2016 Sep;469(3):351-6. doi: 10.1007/s00428-016-1978-x. Epub 2016 Jun 22.

本文引用的文献

1
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.帕博利珠单抗或安慰剂联合放化疗，随后行帕博利珠单抗或安慰剂巩固治疗新诊断的、高危、局部晚期宫颈癌（ENGOT-cx11/GOG-3047/KEYNOTE-A18）：一项随机、双盲、III 期临床研究。
Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20.
2
Gastric-type adenocarcinoma of the endocervix: Potentially overcoming resistant behavior with surgery.宫颈胃型腺癌：手术可能克服耐药行为。
Gynecol Oncol Rep. 2023 Oct 4;50:101282. doi: 10.1016/j.gore.2023.101282. eCollection 2023 Dec.
3
Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.单药PARP抑制剂奥拉帕利成功治疗复发性宫颈癌
Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715. eCollection 2022.
4
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.宫颈胃型腺癌：临床结局和基因组驱动因素。
Gynecol Oncol. 2022 Dec;167(3):458-466. doi: 10.1016/j.ygyno.2022.10.003. Epub 2022 Oct 15.
5
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants.BRCA1 和 BRCA2 致病性变异的癌症风险特征扩展。
JAMA Oncol. 2022 Jun 1;8(6):871-878. doi: 10.1001/jamaoncol.2022.0476.
6
Gastric-type adenocarcinoma of the cervix in patients with Peutz-Jeghers syndrome: a systematic review of the literature with proposed screening guidelines.胃型腺癌的宫颈在患者与 Peutz-Jeghers 综合征：系统评价文献与建议的筛选指南。
Int J Gynecol Cancer. 2022 Jan;32(1):79-88. doi: 10.1136/ijgc-2021-002997. Epub 2021 Dec 13.
7
Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations.大规模平行测序分析 68 例胃型宫颈腺癌，揭示了细胞周期相关基因的突变和潜在的可靶向突变。
Mod Pathol. 2021 Jun;34(6):1213-1225. doi: 10.1038/s41379-020-00726-1. Epub 2020 Dec 14.
8
Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix.宫颈胃型黏液腺癌的遗传学特征。
Mod Pathol. 2021 Mar;34(3):637-646. doi: 10.1038/s41379-020-0614-0. Epub 2020 Jul 8.
9
Revising the WHO classification: female genital tract tumours.修订世卫组织分类：女性生殖器官肿瘤。
Histopathology. 2020 Jan;76(1):151-156. doi: 10.1111/his.13977.
10
Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification.宫颈腺癌：HPV 状态、浸润模式、形态学和分子标志物的整合分类。
Histopathology. 2020 Jan;76(1):112-127. doi: 10.1111/his.13995.